2 / 6
Page 16
allied
academies
J Clin Exp Tox 2017 Volume 1 | Issue 2
Toxicology and Pharmacology
November 01-02, 2017 | Toronto, Canada
International Conference on
A
lcohol consumption remains a significant risk factor for
thedevelopment of liver damage inpatientsbeing treated
with pegylated interferon (PEG-IFN-α), in the presence or
absence of ribavirin as well the protease inhibitors for viral
hepatitis B, C (HBV, HCV) and human immunodeficiency viral
infections (HIV) or HCV-HIV. The daily alcohol consumption
of >60 mg/day provides a significant risk factor for the
development of cirrhosis, hepatocellular carcinoma and the
increased risk of mortality. This applies to treatments that
used a variety of the non-nucleoside reverse transcriptase
inhibitor class. Severe hepatotoxicity [defined as AST or ALT
being at >5 upper limit of normal] is also seen in patients who
are co-infected HIV/HCV and are being treated with indinavir,
nelfinavir, ritonavir, saquinavir, or ritonavir plus saquinavir. In
highly active antiretroviral therapies (HAART) that included
PI-based, NNRTI-based, and PI- plus NNRTI-based therapies,
alcohol abuse is an identified risk factor for the drug-induced
liver injury (DILI). Alcohol misuse and over the counter drugs
(sulphonamides, antipyreticsor anti-inflammatory) may lead
to DILI and liver transplant. Also misuse of illicit drugs in the
presence or absence of alcohol lead to drug-induced liver
injury.
Speaker Biography
Manuela G Neuman is Adjunct Professor of Pharmacology and Toxicology, Associated
Global Health at the University of Toronto, and a Professor at the Carol Davila University
of Medicine and Pharmacy (UMF), Bucharest. She is the Founder and CEO of In Vitro
Drug Safety and Biotechnology, Toronto. She holds an MSc in Biology from University of
Bucharest, a Post-doctoral Fellowship from the Institute of Inframicrobiology, Faculty
of Medicine, Bucharest, PhD in Physiology and Pharmacology from Tel-Aviv University.
She also completed her Post-doctoral fellowship in Clinical Chemistry, Hepatology,
Immunology, Gastroenterology and Clinical Pharmacology at the University of
Toronto, Toronto, Canada. Her research was in the Department of Biochemistry
and in the Chemotherapy Institute, while she acted as a Biochemist at the “Victor
Babes” Hospital in Bucharest. In these positions of pharmaceuticals, she had “hands
on” daily routine, as well as, acting as a Laboratory Scientific Director making liaison
between the laboratory and drug discovery platforms and translational research. She
has published extensively in the areas of therapeutic and drug of (use and misuse)
monitoring, new biologic and their monitoring in clinical practice, pharmacogenetic
and immunopharmacogentic clinical applications, drug-induced liver and skin adverse
reactions, liver immunology, hepatocellular carcinoma and inflammatory bowel
disease. Since 1992, she is a member of the IATDMCT.
e:
m_neuman@rogers.comManuela G Neuman
University of Toronto, Canada
Drugs of misuse and therapeutics a deadly combination